A disrupted function of AMPs in patients with AD was first reported by Ong et al. [83], who described the decreased expression of human cathelicidin LL-37 and hBD-2 in patients with AD compared with patients with psoriasis. The gene discussed is CAMP; the disease is Alzheimer disease.